Review of economic modeling evidence from NICE appraisals of rare disease treatments for spinal muscular atrophy.

This article aims to contribute to the development of evidence that can be used as guidance to inform resource allocation decisions for RDTs for SMA, but also to be a resource about approaches for the generation, analysis and interpretation of economic modelling evidence for RDTs more broadly.